AzTrials
AzTrials

ObesityNCT03860623

Effect of Oral Feeding on Gastric Emptying, Gut Blood Flow, and Hormone Responses in Obese and Healthy Weight Subjects

An observational study of Obesity, run by University of Nottingham at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Obesity is a complicated condition that is poorly understood. The aim of this study is to increase our knowledge of how the condition may arise, and what makes obese people remain obese. Read more about this study

Who is it for?
Ages 18 to 60 years, men onlyHealthy volunteers can take part
Conditions the study is for
Obesity
How many people
20 participants
Where
1 siteUnited Kingdom
Study dates
7 Nov 2018to 28 Oct 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Study population: Recruitment will be from the male population residing within 20 miles of the research site. This will include those from Nottinghamshire, Leicestershire and Derbyshire, UK

Who may be able to join

  • BMI 30-40 kg/m2
  • BMI 18-25 kg/m2; those with BMI up to 28kg/m2 will be included if waist circumference is <96cm.
  • Males
  • Aged 18-60yrs

Who cannot join

  • Acute illness in the preceding 6 weeks
  • Taking regular medication
  • History of deep vein thrombosis or clotting disorders
  • Hypertension
  • Diabetes
  • Any clinically significant findings at screening
Show all 11Show fewer
  • History of substance abuse
  • Demonstrating factors precluding safe MRI
  • History of gastrointestinal motility disorders (e.g. gastroesophageal reflux disease -irritable bowel syndrome, gastroparesis, sphincter of Oddi dysfunction, etc.)
  • Previous thoracic or abdominal surgery.
  • Those who report having ≤3 bowel movements/week or >2/day.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Queens Medical Centre

    Nottingham, Notts, NG72UH

Other trials in United Kingdom

About this study

Official title: The Effect of Oral Feeding on Gastric Emptying, Small Bowel Water Content, Superior Mesenteric Artery Blood Flow, Plasma Hormone Concentrations and Blood Volume in Obese and Healthy Weight Subjects.

Obesity is a complicated condition that is poorly understood. The aim of this study is to increase our knowledge of how the condition may arise, and what makes obese people remain obese.

We will be investigating 12 people who are overweight and comparing them to 12 people who are lean, to look at how quickly food empties out of the stomach (gastric emptying) and travels through the gut, what the blood flow to the gut is, and also to examine the hormones which are involved in determining how full people feel after eating. In order to do this, we will be using a magnetic resonance imaging (MRI) scanner, and performing blood tests.

The rate of gastric emptying may have an impact on satiety (how full one feels) and has been implied in the development of obesity. This effect has been shown to impact on subsequent meal intake to a greater degree in overweight subjects, and may be due to a difference in gastric emptying of food in overweight individuals, or to hormones such as ghrelin, glucagon-like peptide 1, and Peptide YY.

Read the detailed description

The World Health Organisation (WHO) has deemed being overweight or obese as the fifth leading cause for global deaths, with more than 1.9 billion adults being defined as overweight, and 600 million defined as being obese. Conditions associated with obesity, such as stroke, type 2 diabetes, certain cancers, cardiovascular, fatty liver and airway disease can lead to premature death. Obesity results from an imbalance in energy intake versus expenditure, and fat mass accumulates. Studies have indicated that obese animals have a faster gastric emptying time, a weaker contraction of the duodenum, but a stronger contraction and relaxation of the ileum, with associated changes in gastrointestinal neurohormonal levels. The rate of gastric emptying may have an impact on feelings of satiety and has been implied in the pathogenesis of obesity. Moreover, mesenteric blood flow increases 3-fold following a meal and in a swine experimental model, a reduction in weight gain was seen when blood flow was intentionally limited to the gut using flow-restricting endovascular stenting. The authors concluded that this intervention may play a role in the treatment of obesity where other interventions have failed or are inappropriate; however the role of blood flow to the gut in obese individuals is important to elucidate. We hypothesize that nutrient absorption in obese and healthy weight individuals after a standardized meal is determined by differences in gastric emptying and mesenteric blood flow which give rise to different insulin, glucose and gut hormone responses. These may be contributory mechanisms to the evolution or maintenance of obesity.

The aim of this study is to establish the effects of food ingestion on gastric emptying, gallbladder emptying, small bowel water content and splanchnic blood flow as measured by serial magnetic resonance imaging (MRI) in the context of changes in plasma gastrointestinal hormone secretion in human subjects who are obese or healthy weight. In addition, this pilot study will provide the data necessary to power a larger study investigating methods of dietary manipulation in the treatment of obesity.

Method: In order to normalize the pre-study diet, volunteers will have consumed a standard diet for the 3 days immediately before the study visit, which will be based on foods in their normal diet and will be designed to meet their estimated energy requirements and provide 15% of total daily energy intake as protein, 35% as fat and 50% as carbohydrate. Participants will report at 0800 hours following a fast from midnight and after having abstained from alcohol, nicotine, and caffeine from 1800 hours the day before. On arrival, participants will be given a drink of water (200ml). A retrograde cannula will be inserted into a dorsal foot vein after prior intradermal infiltration of 1% lidocaine, with the foot placed in a magnetic resonance (MR) compatible warming box that we have developed, for arterialized-venous blood sampling. Prior to baseline blood sampling, participants will undergo a magnetic resonance imaging (MRI) scan to determine baseline values for superior mesenteric artery (SMA) blood flow, small bowel water content and gastric fluid and gas volumes. Liver fat, visceral fat and subcutaneous fat volumes will also be assessed at this time. Subsequently, a blood sample will be drawn for analysis of concentrations of hemoglobin, glucose, insulin, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), ghrelin and peptide YY (PYY). Serum osmolality will also be measured and subjective appetite assessed using visual analogue scales. The participants will then be given the test meal (in an upright, seated position) and asked to consume it within 15 minutes. The test meal will be comprised of pasta, cheese and tomato sauce, and provides 13% of total energy (E) from protein, 39%E fat, and 48%E carbohydrate.

Following the test meal (time = 0 minutes), subjective appetite will be measured as before, then participants will be scanned at 30 minute intervals for 4 hours to assess gastric emptying, gastric accommodation, gastric motility and small bowel water content, as well as SMA blood flow. Blood samples will be drawn at 15 minutes, then every half hour until 240 minutes after the test meal, with a final blood sample taken at 300 minutes. Subjective appetite will be assessed every hour over the 300 minute study.

Conditions
Obesity
Keywords
satiety, gut blood flow, gastric emptying, obesity, incretin hormones
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03860623
Study groupRoleWhat they receive
OverweightOtherwise healthy overweight and obese men (BMI 30-40kg/m2) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating
Normal WeightHealthy normal weight men (BMI 18-25kg/m2, but including those with BMI up to 28kg/m2 if waist circumference <96cm) aged 18 to 60 years Group will consume a standard meal (Feeding) and measurements will be made before (baseline) and for 300 minutes after eating

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gastric emptying rate

    time taken for a standard meal to empty from the stomach, assessed by serial volume measurements of the stomach using magnetic resonance imaging

    Measured: 240 minutes after feeding

Secondary outcomes (23)
  1. Stomach volume in the fasted state

    volume of the stomach measured by magnetic resonance imaging

    Measured: baseline

  2. Superior mesenteric artery (SMA) blood flow in the fasted state

    blood flow in the SMA assessed using magnetic resonance imaging

    Measured: baseline

  3. superior mesenteric artery (SMA) blood flow response to feeding

    blood flow response to feeding, determined in the SMA every half hour using magnetic resonance imaging

    Measured: 240 minutes after feeding

  4. Fasting blood glucose concentration

    whole blood glucose concentration assessed using a Hemocue glucose analyser

    Measured: before feeding

  5. Blood glucose response to feeding

    whole blood glucose concentration response to feeding, assessed by serial sampling using a Hemocue glucose analyser

    Measured: 300 minutes after feeding

  6. Fasting insulin concentration

    serum insulin concentration in the fasted state measured at a later date using a radio-immunoassay (RIA)

    Measured: baseline

  7. serum insulin response to feeding

    serum insulin concentration response to feeding, assessed by serial sampling and measured at a later date using a RIA

    Measured: 300 minutes after feeding

  8. Fasting plasma GLP-1 concentration

    Plasma GLP-1 concentration in the fasted state, measured at a later date using an enzyme-linked immunosorbent assay (ELISA)

    Measured: baseline

  9. Plasma GLP-1 response to feeding

    Plasma GLP-1 concentration response to feeding, assessed by serial sampling and measured at a later date using an ELISA

    Measured: 300 minutes after feeding

  10. Fasting plasma GLP-2 concentration

    Plasma GLP-2 concentration in the fasted state, measured at a later date using an enzyme-linked immunosorbent assay (ELISA)

    Measured: baseline

  11. Plasma GLP-2 response to feeding

    Plasma GLP-2 concentration response to feeding, assessed by serial sampling and measured at a later date using an ELISA

    Measured: 300 minutes after feeding

  12. Fasting plasma Ghrelin

    Plasma Ghrelin concentration in the fasted state measured at a later date using a RIA

    Measured: baseline

  13. Plasma Ghrelin response to feeding

    Plasma Ghrelin concentration response to feeding assessed by serial sampling and measured at a later date using a RIA

    Measured: 300 minutes after feeding

  14. Fasting plasma peptide YY (PYY)

    Plasma PYY concentration in the fasted state measured at a later date using a RIA

    Measured: baseline

  15. Plasma peptide YY (PYY) response to feeding

    Plasma PYY concentration response to feeding assessed by serial sampling and measured at a later date using a RIA

    Measured: 300 minutes after feeding

  16. Subjective satiety in the fasted state

    Satiety of individuals in the fasted state will be assessed using 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and how full do you feel')

    Measured: baseline

  17. Subjective satiety after eating

    Satiety immediately after eating the standard meal will be assessed using 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and 'how full do you feel')

    Measured: immediately after eating the standard meal

  18. Subjective satiety response to eating

    The satiety response to the standard meal will be assessed over the 300 minute study period using hourly collection of 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and 'how full do you feel')

    Measured: 300 minutes after eating

  19. visceral adiposity

    amount of visceral fat present, determined by MRI of the torso

    Measured: baseline

  20. subcutaneous adiposity

    thickness of the subcutaneous fat layer on the torso, determined by MRI

    Measured: before feeding

  21. hepatic lipid content

    liver triacylglyceride content will be estimated using proton magnetic resonance spectroscopy

    Measured: baseline

  22. Attrition rate

    Number of participants completing the protocol as a proportion of those who were recruited to the study

    Measured: 1 year

  23. Recruitment rate

    number of people volunteering to take part in the study as a proportion of those expressing initial interest

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2019
  2. Study start7 Nov 2018
  3. Primary completion31 Dec 2021
  4. Study completion28 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03860623
Sponsor's protocol ID
A16042015
Status last verified
Nov 2025
First submitted
25 Feb 2019
Last updated
4 Dec 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Fu XY, Li Z, Zhang N, Yu HT, Wang SR, Liu JR. Effects of gastrointestinal motility on obesity. Nutr Metab (Lond). 2014 Jan 7;11(1):3. doi: 10.1186/1743-7075-11-3.

    PubMed 24398016
  • Vatner SF, Franklin D, Van Citters RL. Mesenteric vasoactivity associated with eating and digestion in the conscious dog. Am J Physiol. 1970 Jul;219(1):170-4. doi: 10.1152/ajplegacy.1970.219.1.170. No abstract available.

    PubMed 4393203
  • Alyami J, Spiller RC, Marciani L. Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterol Motil. 2015 Dec;27(12):1687-92. doi: 10.1111/nmo.12726.

    PubMed 26598049
  • Hoad CL, Parker H, Hudders N, Costigan C, Cox EF, Perkins AC, Blackshaw PE, Marciani L, Spiller RC, Fox MR, Gowland PA. Measurement of gastric meal and secretion volumes using magnetic resonance imaging. Phys Med Biol. 2015 Feb 7;60(3):1367-83. doi: 10.1088/0031-9155/60/3/1367. Epub 2015 Jan 16.

    PubMed 25592405
  • Totman JJ, Marciani L, Foley S, Campbell E, Hoad CL, Macdonald IA, Spiller RC, Gowland PA. Characterization of the time course of the superior mesenteric, abdominal aorta, internal carotid and vertebral arteries blood flow response to the oral glucose challenge test using magnetic resonance imaging. Physiol Meas. 2009 Oct;30(10):1117-36. doi: 10.1088/0967-3334/30/10/011. Epub 2009 Sep 16.

    PubMed 19759401
  • Simpson EJ, Althubeati S, Cordon S, Hoad C, Bush D, Eldeghaidy S, Gowland PA, Macdonald IA, Lobo DN. The effect of oral feeding on gastrointestinal function, motility and appetite-regulating hormones, insulin, glucose and satiety in normal weight individuals and those with obesity. Clin Nutr. 2025 Sep;52:62-71. doi: 10.1016/j.clnu.2025.07.008. Epub 2025 Jul 8.

    PubMed 40714600

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gastric emptying rate (time frame: 240 minutes after feeding). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03860623, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in